{"organizations": [], "uuid": "504f4a52b361cb0500a55652b98d79bd85ee61d9", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-ligand-posts-q4-adjusted-earnings/brief-ligand-posts-q4-adjusted-earnings-per-share-1-31-idUSASB0C6QF", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Posts Q4 Adjusted Earnings Per Share $1.31", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T23:13:00.000+02:00", "replies_count": 0, "uuid": "504f4a52b361cb0500a55652b98d79bd85ee61d9"}, "author": "", "url": "https://www.reuters.com/article/brief-ligand-posts-q4-adjusted-earnings/brief-ligand-posts-q4-adjusted-earnings-per-share-1-31-idUSASB0C6QF", "ord_in_thread": 0, "title": "BRIEF-Ligand Posts Q4 Adjusted Earnings Per Share $1.31", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "ligand pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ligand", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 9:15 PM / Updated 10 minutes ago BRIEF-Ligand Posts Q4 Adjusted Earnings Per Share $1.31 Reuters Staff Feb 21 (Reuters) - Ligand Pharmaceuticals Inc: * LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS * Q4 ADJUSTED EARNINGS PER SHARE $1.31 * Q4 GAAP LOSS PER SHARE $0.33 * SEES FY 2018 REVENUE ABOUT $164 MILLION * Q4 REVENUE $50.5 MILLION * ‍AS OF DECEMBER 31, 2017, LIGAND HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $201.7 MILLION​ * ‍ESTIMATES THAT CASH EXPENSES FOR 2018 WILL BE IN RANGE OF $34 MILLION TO $35 MILLION​ * WITH REVENUE OF $164 MILLION, ADJUSTED EARNINGS PER DILUTED SHARE WOULD BE ABOUT $4.22 FOR 2018​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T23:13:00.000+02:00", "crawled": "2018-02-21T23:33:42.000+02:00", "highlightTitle": ""}